<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144521</url>
  </required_header>
  <id_info>
    <org_study_id>MRA213JP</org_study_id>
    <nct_id>NCT00144521</nct_id>
  </id_info>
  <brief_title>Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)</brief_title>
  <official_title>A Double-Blind, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the clinical efficacy and safety of MRA in a
      double-blind, parallel-group, controlled study using MRA or methotrexate (MTX) in rheumatoid
      arthritis (RA) patients with MTX administered.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">August 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of ACR 20% improvement</measure>
    <time_frame>week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events and adverse drug reactions</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of DAS28</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time course of the frequency of ACR 20%, 50% and 70%</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRA(Tocilizumab)</intervention_name>
    <description>8mg/kg/4week(i.v.)for 24 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRA placebo</intervention_name>
    <description>0mg/kg/4week(i.v.) for 24 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>8mg/week(p.o.) for 24 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX placebo</intervention_name>
    <description>0mg/week(p.o.) for 24 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Diagnosis of RA based on the 1987 classification criteria of the American College of
             Rheumatology (ACR)

          -  Disease duration of 6 months or more

          -  Treated with 8 mg/week of MTX for at least 8 weeks immediately preceding enrollment,
             and continued on this treatment up to initiation of the study drug

          -  Active disease at enrollment (less than 2 weeks before initiating treatment with a
             study drug), Which is defined as having at least 6 tender and 6 swollen joints among
             49 and 46 joints stipulated by the Japanese Rheumatism Foundation's Drug Evaluation
             Committee and ESR at least 30 mm/hr and CRP not less than 1.0 mg/dL

        Exclusion criteria

          -  Assessed as having Class IV Steinbrocker functional activity in the 4 weeks preceding
             treatment with the study drug

          -  Treated with infliximab, etanercept or leflunomide in the 12 weeks preceding treatment
             with the study drug

          -  Received any of the following therapies in the 2 weeks preceding initiation of
             treatment with the study drug.

               1. Administration of any DMARD or immunosuppressant other than MTX

               2. Administration of corticosteroids exceeding 10 mg/day as prednisolone

               3. Dose escalation or initiation of corticosteroids

          -  Received any of the following therapies in the 4 weeks preceding treatment with the
             study drug

               1. Plasma exchange therapy

               2. Surgical treatment (operation, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takahiro Kakehi</last_name>
    <role>Study Director</role>
    <affiliation>Chugai Pharmaceutical</affiliation>
  </overall_official>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>January 30, 2009</last_update_submitted>
  <last_update_submitted_qc>January 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chugai Pharmaceutical</name_title>
    <organization>Chugai Pharmaceutical</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

